protein

Recombinant Myosin Heavy Chain 6, Cardiac Muscle, Alpha (MYH6)

MBS2012470

0.01 mg

195 USD

Recombinant Protein

Recombinant Myosin Heavy Chain 6, Cardiac Muscle, Alpha (MYH6)

Myosin Heavy Chain 6, Cardiac Muscle, Alpha (MYH6)

Myosin-6; Myosin-6; myosin-6; myHC-alpha; myosin heavy chain 6; myosin heavy chain, cardiac muscle alpha isoform; myosin, heavy polypeptide 6, cardiac muscle, alpha; myosin heavy chain polypeptide 6 cardiac muscle adult; myosin heavy chain, polypeptide 6, cardiac muscle, alpha; myosin, heavy chain 6, cardiac muscle, alpha; Myosin heavy chain 6; Myosin heavy chain, cardiac muscle alpha isoform

MYH6

Myh6; Myh6; Myhca; MyHC-alpha

MYH6_RAT

E Coli

1938

The sequence of the target protein is listed below. QECR NAEEKAKKAI TDAAMMAEEL KKEQDTSAHL ERMKKNMEQT IKDLQHRLDE AEQIALKGGK KQLQKLEARV RELENELEAE QKRNAESVKG MRKSERRIKE LTYQTEEDKK NLVRLQDLVD KLQLKVKAYK RQAEEAEEQA NTNLSKFRKV QHELDEAEER ADIAESQVNK LRAKSRDIGA KQKMHDEE

> 95%

Supplied as lyophilized form in 10mM PBS, pH7.4, containing 1mM DTT, 5% trehalose, 0.01% sarcosyl and preservative.

Avoid repeated freeze/thaw cycles. Store at 2-8 degree C for one month. Aliquot and store at -80 degree C for 12 months. Stability Test: The thermal stability is described by the loss rate of the targetprotein. The loss rate was determined by accelerated thermal degradation test,that is, incubate the protein at 37 degree C for 48h, and no obvious degradation andprecipitation were observed. (Referring from China Biological Products Standard,which was calculated by the Arrhenius equation.) The loss of this protein is lessthan 5% within the expiration date under appropriate storage condition.

SDS-PAGE, Western Blot (WB), ELISA (EIA), Immunoprecipitation (IP)

Organism: Rattus norvegicus (Rat). Expression System: Prokaryotic expression. Residues: Gln1747~Glu1938 (Accession # P02563) with N-terminal His-Tag

Endotoxin Level: <1.0EU per 1ug (determined by the LAL method). Usage: Reconstitute in sterile ddH2O. Predicted isoelectric point: 6.8

127741

P02563.2

P02563

24.0kDa

Adrenergic Signaling In Cardiomyocytes Pathway (908278); Adrenergic Signaling In Cardiomyocytes Pathway (909696); Cardiac Muscle Contraction Pathway (93346); Cardiac Muscle Contraction Pathway (93992); Dilated Cardiomyopathy Pathway (121476); Dilated Cardiomyopathy Pathway (121285); Hypertrophic Cardiomyopathy (HCM) Pathway (114014); Hypertrophic Cardiomyopathy (HCM) Pathway (106591); Muscle Contraction Pathway (935714); Striated Muscle Contraction Pathway (935715)

heavy chain of myosin; involved in muscle contraction [RGD, Feb 2006]

MYH6: Muscle contraction. Defects in MYH6 are the cause of atrial septal defect type 3 (ASD3). ASD3 is a congenital heart malformation characterized by incomplete closure of the wall between the atria resulting in blood flow from the left to the right atria. Defects in MYH6 are the cause of familial hypertrophic cardiomyopathy type 14 (CMH14). It is a hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations,and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death. Defects in MYH6 are the cause of cardiomyopathy dilated type 1EE (CMD1EE). It is a disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. Defects in MYH6 are the cause of susceptibility to sick sinus syndrome type 3 (SSS3). The term sick sinus syndrome encompasses a variety of conditions caused by sinus node dysfunction. The most common clinical manifestations are syncope, presyncope, dizziness, and fatigue. Electrocardiogram typically shows sinus bradycardia, sinus arrest, and/or sinoatrial block. Episodes of atrial tachycardias coexisting with sinus bradycardia ( tachycardia-bradycardia syndrome ) are also common in this disorder. SSS occurs most often in the elderly associated with underlying heart disease or previous cardiac surgery, but can also occur in the fetus, infant, or child without heart disease or other contributing factors. MYH6 variations are associated with susceptibility to sick sinus syndrome (PubMed:21378987). The lifetime risk of being diagnosed with sick sinus syndrome is higher for carriers of variant p.Arg721Trp than for non-carriers (PubMed:21378987). Protein type: Motility/polarity/chemotaxis; Motor. Cellular Component: nucleoplasm; focal adhesion; myofibril; mitochondrion; cytoplasm; stress fiber; muscle myosin complex; nucleus; Z disc; myosin complex. Molecular Function: microfilament motor activity; calmodulin binding; identical protein binding; protein homodimerization activity; protein heterodimerization activity; ATPase activity; actin-dependent ATPase activity; actin binding; protein kinase binding; calcium-dependent ATPase activity; ATP binding. Biological Process: adult heart development; striated muscle contraction; in utero embryonic development; atrial cardiac muscle morphogenesis; metabolic process; actin filament-based movement; regulation of heart rate; Wnt receptor signaling pathway through beta-catenin; sarcomere organization; regulation of heart contraction; muscle filament sliding; visceral muscle development; BMP signaling pathway; regulation of ATPase activity; myofibril assembly; muscle contraction; response to heat; cardiac muscle fiber development; regulation of blood pressure; ventricular cardiac muscle morphogenesis; regulation of the force of heart contraction

0.01 mg

195 USD

0.05 mg

420

0.1 mg

650